How Much Does the P-tau217 Blood Test Cost?

A p-tau217 blood test typically runs between about $200 and $700 out of pocket in the United States, though exact pricing depends on the laboratory, the specific assay platform used, and whether insurance covers any portion. That range makes the test far cheaper than the alternatives it is designed to partially replace, like amyloid PET scans that can cost several thousand dollars per session. But the sticker price only scratches the surface of what you actually want to know, because what you end up paying hinges on insurance decisions that are still in flux, the clinical context in which the test is ordered, and whether the result saves or adds further diagnostic steps.

Why the Price Is Not a Single Number

There is no universal price list for p-tau217 testing because several different companies offer competing assays built on different technology. Some use mass spectrometry, which measures the ratio of phosphorylated tau to total tau (sometimes called %p-tau217). Others rely on immunoassays that measure absolute concentrations of the phosphorylated protein. A head-to-head comparison of these two approaches in nearly a thousand participants found that the mass spectrometry method had higher overall accuracy for detecting amyloid pathology (about 88% versus 82%) and was better at identifying people who truly had amyloid buildup in their brains.¹ The mass spectrometry platforms tend to sit at the higher end of the cost range, in part because the equipment and expertise they require are more specialized.

Cost-effectiveness modeling in a Japanese healthcare context used a blood biomarker cost range of $100 to $700 when examining different diagnostic pathways, which gives a reasonable sense of the global spread.² Where your test falls in that range depends on the lab, the technology behind their assay, and what the market will bear in your region. Some labs bundle interpretation with the test fee; others charge separately for a clinical consultation to review the results.

Insurance Coverage Is Still Catching Up

The biggest variable in what you actually pay is whether your insurer covers any of the cost, and right now the answer is inconsistent. Medicare has not established broad national coverage for p-tau217 blood biomarker tests. Some private insurers have begun covering the test under prior authorization, particularly when it is ordered by a specialist for a patient already showing cognitive symptoms. But many people who want the test, especially those seeking it for early screening before symptoms appear, find themselves paying entirely out of pocket.

This coverage gap is especially frustrating because the test exists, in large part, to reduce the need for far more expensive procedures. Without consistent reimbursement policies, patients and clinicians face an awkward choice between a cheaper blood test that they pay for themselves and a more expensive PET scan that insurance might actually cover. The economics only make sense on a system level if insurers treat blood biomarkers as the screening step they were designed to be.

How It Compares to PET Scans and Spinal Fluid Tests

The clearest way to put the price in perspective is to look at what it replaces. An amyloid PET scan, the current gold standard for detecting Alzheimer’s-related amyloid plaques, typically costs between $3,000 and $7,000 depending on the facility. A lumbar puncture to collect cerebrospinal fluid for biomarker analysis is less expensive than PET but still runs well over $1,000 when you factor in the procedure itself, lab fees, and the clinical setting required.

A cost-effectiveness analysis found that using blood biomarkers as a triage step before PET scanning would identify over 98% of amyloid-positive patients at a lower average cost per diagnosis than going straight to PET (roughly $8,868 per confirmed positive diagnosis with the blood-first approach compared to $10,345 with PET alone).³ The savings grow dramatically when PET scan availability is limited. In scenarios where only half of patients could access PET scans, blood biomarker testing identified over 90% more positive cases at an incremental cost of about $3,484 per additional diagnosis, well below the average cost of a PET-based diagnosis.³

In the Japanese analysis, the cost savings from using blood biomarkers ranged from 40% to 79% compared to PET and from 6% to 74% compared to inpatient cerebrospinal fluid collection, depending on where the blood test price fell within that $100 to $700 range.² The message across these different economic models is consistent: even at the high end of the blood test’s price range, it saves the healthcare system substantial money by reducing reliance on expensive imaging and invasive procedures. A separate analysis reinforced this, concluding that p-tau217 alone provides a cost-effective screening alternative to PET, even when used without additional plasma biomarkers in combination.⁴

What You Get for the Money

A reasonable question is whether a few hundred dollars buys you something clinically meaningful or just an uncertain screening result that leads to more tests anyway. The evidence here is genuinely encouraging. A systematic review and meta-analysis of studies on plasma p-tau217 found that it detected amyloid pathology with about 82% sensitivity and 86% specificity, and tau pathology with roughly 83% sensitivity and 83% specificity.⁵ Those numbers mean the blood test catches most people who have Alzheimer’s pathology and correctly rules out most people who do not.

Individual studies have reported even higher accuracy. One multi-cohort validation found that p-tau217 predicted abnormal amyloid PET results with an area under the curve above 0.92 across different study populations, and performed similarly well for predicting abnormal tau deposition.⁶ An area under the curve of 0.92 or higher is considered excellent diagnostic performance for any biomarker test. These are not vague screening signals; they are actionable results that can meaningfully guide the next steps in diagnosis.

A study using a fully automated testing platform found that accuracy held up well not just in specialist memory clinics but also in primary care settings, where p-tau217 reached about 85% accuracy with positive predictive values around 82% and negative predictive values around 88%.⁷ In specialist settings the accuracy climbed to roughly 89% to 91%.⁷ The fact that performance stays strong outside of elite research centers matters enormously for how the test will work in practice, because most people being evaluated for cognitive decline start with their primary care doctor, not a neurologist at an academic medical center.

Health Conditions That Can Skew Your Results

One underappreciated cost consideration is whether the test will give you an accurate result in the first place, because certain common health conditions can interfere with the measurement. If a false result leads to unnecessary follow-up testing or, worse, a missed diagnosis, the initial savings from choosing a blood test over a PET scan evaporate.

Kidney dysfunction is the biggest concern. A study examining this found that in people without Alzheimer’s amyloid pathology, those with reduced kidney function (an estimated glomerular filtration rate below 60) had significantly elevated p-tau217 levels. Depending on the assay used, the measured p-tau217 concentration increased by 19% to 55% in people with moderate kidney impairment compared to those with normal function.⁸ That kind of inflation could push a healthy person’s result past the threshold used to flag possible Alzheimer’s pathology.

A separate investigation found that anemia also elevated p-tau217 concentrations, creating similar potential for false positives. However, the %p-tau217 ratio measurement (comparing phosphorylated to total tau) was more resilient to these confounders, with kidney dysfunction and anemia having no significant effect on the ratio-based measurement.⁹ The practical takeaway is that the specific assay platform matters for people with kidney problems or anemia. Ratio-based tests may produce more reliable results for those individuals, though they may also sit at a different price point. Obesity, by contrast, did not meaningfully interfere with standard test interpretation.⁹

If you have chronic kidney disease or are anemic, it is worth asking the ordering clinician which assay platform the lab uses and whether adjusted cutoff thresholds will be applied. Some labs are already implementing condition-specific thresholds, but the practice is not yet universal. Getting the wrong assay for your medical profile could mean paying a few hundred dollars for a result that needs to be confirmed by further testing anyway.

Who Has Been Left Out of the Validation Research

The test’s performance numbers are strong overall, but they come with an important asterisk. Most of the large validation studies that produced those accuracy figures were conducted in predominantly non-Hispanic White populations. The degree to which the results hold across diverse populations has not been firmly established, and that gap matters because Black and Hispanic older adults face disproportionately high rates of dementia while being markedly underrepresented in biomarker research.¹⁰

This is not just an academic concern about generalizability. If the test performs differently in some populations, whether because of biological variation, differences in comorbidity profiles, or factors researchers have not yet identified, then a given price tag buys a less informative test for those groups. People paying the same amount deserve the same confidence in their result. Research is beginning to address this gap, with community-based studies evaluating p-tau217 across racial and ethnic groups, but the field has a long way to go before the evidence base is truly representative.

Access is another dimension. Blood biomarker tests are being positioned as a way to democratize Alzheimer’s diagnosis by moving it out of specialized imaging centers and into ordinary clinics. In theory, a blood draw is simpler, cheaper, and more accessible than a PET scan, especially for people in rural areas or those who cannot tolerate the hours-long process of PET imaging. But if the test is not validated in your population, or if reimbursement policies leave you paying entirely out of pocket, the promise of broader access remains partially theoretical.

The Emerging Role in Clinical Trials

One area where p-tau217 blood tests are already producing concrete cost savings is in clinical trials for Alzheimer’s therapies. Recruiting participants for trials of anti-amyloid drugs requires confirming that each enrollee actually has amyloid pathology, traditionally through expensive PET scans. Blood biomarker screening has begun to change that calculus. One pharmaceutical company reported that using a p-tau217 screening assay reduced overall clinical trial screening costs by 40% in a phase 2 trial of a drug for early Alzheimer’s disease.

Those savings matter beyond the trial budget. The faster and cheaper it is to screen potential trial participants, the faster new treatments can be tested and brought to market. Clinical trial costs are ultimately borne by the healthcare system and patients who pay for approved drugs, so anything that streamlines the research pipeline has downstream economic effects that reach far beyond the lab.

Paying for Repeat Testing Over Time

Most of the cost discussion focuses on a single test, but Alzheimer’s disease unfolds over years or decades, and there is growing interest in using p-tau217 levels to track disease progression over time rather than just making a one-time diagnostic call. Longitudinal research has shown that plasma p-tau217 levels change as the disease advances, rising in individuals who go on to develop cognitive impairment.¹¹ This makes the test a candidate not just for diagnosis but for monitoring, similar to how hemoglobin A1c tracks diabetes control over time.

If serial testing becomes part of standard Alzheimer’s care, the cumulative cost becomes relevant. Two or three tests over several years at a few hundred dollars each is a very different financial proposition than a single screening test. Whether this kind of longitudinal monitoring will be covered by insurance, and at what intervals, remains an open question. The science supporting serial measurement is still maturing, and no formal clinical guidelines yet recommend a specific retesting schedule.

When the Test Might Not Be Worth the Cost for You

Not everyone who is worried about memory problems needs a p-tau217 blood test, and spending several hundred dollars on one is not always the most useful next step. The test is most informative when there is already a clinical suspicion that cognitive symptoms might be caused by Alzheimer’s disease specifically, as opposed to other common causes of memory trouble like depression, medication side effects, thyroid disorders, or normal aging. If those possibilities have not been ruled out through a thorough clinical evaluation first, a biomarker result, positive or negative, can be more confusing than clarifying.

People with no symptoms who simply want to know their risk face a different calculation. A negative result can offer genuine reassurance, but a positive result in a cognitively healthy person means Alzheimer’s pathology is present in the brain without yet causing symptoms. That is valuable information for clinical trial enrollment and advance planning, but it comes with psychological weight, and the newer anti-amyloid therapies that might act on this information are themselves expensive, carry risks, and have limited availability. The cost of the blood test is just the entry point into a much larger and costlier clinical pathway.

For people already showing clear symptoms of moderate to advanced dementia, the test may also have limited added value. At that stage, the clinical picture is often clear enough that confirming amyloid status does not change management. The sweet spot for the test’s clinical and economic value is in the early and uncertain phases: mild cognitive complaints, ambiguous clinical presentations, and situations where knowing whether amyloid pathology is present would genuinely change the treatment plan.